Benefit of switching from a protease inhibitor (PI) to nevirapine in PI-experienced patients suffering acquired HIV-related lipodystrophy syndrome (AHL): Interim analysis at 3 months of follow-up

Antiviral Therapy

Volumn 4, Issue SUPPL. 3, 1999, Pages 23-28

  Negredo, Eugenia ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; CHOLESTEROL; DIDANOSINE; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TRIACYLGLYCEROL;

ADULT; ARM; BODY BUILD; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FACE; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LIPODYSTROPHY; MALE; METABOLIC DISORDER; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RASH; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS INACTIVATION;

ADULT; ANTHROPOMETRY; ANTI-HIV AGENTS; BODY SIZE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; MALE; NEVIRAPINE; PROSPECTIVE STUDIES; QUALITY OF LIFE; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 0032755358     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (5)

1. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ & Cooper DA. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12:F51-F58.
2. Walli R, Herford O, Michl GM, Demant T, Jager H, Dieterle C, Bogner JR, Landgraf R & Goebel FD. Treatment with protease inhibitor associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS 1998; 12:F167-F173.
3. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ & Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999; 353:2093-2099.
4. Martinez E, Conget I, Lozano L, Casamitjana R & Gatell JM. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS 1999; 13:805-810.
5. Romeu J, Tural C, Sirera G, Rego MJ, Negredo E, Bonjoch A, Jou A, Cruz L & Clotet B. Cumulative risk for developing hyperlipidemia in HIV-infected patients treated with protease inhibitors. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, Calif., USA. 26-29 September, 1999. Abstract 1293